SCHEMBL6817839

SCHEMBL6817839

CCCCNc1nc(Cl)nc2c1ncn2CCC

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 13/20 0.67
HDAC2 Q92769 12/20 0.67
CTSL P07711 5/20 0.59
HDAC8 Q9BY41 11/20 0.54
HDAC3 O15379 9/20 0.54
HDAC4 P56524 9/20 0.54
HDAC7 Q8WUI4 9/20 0.54
HDAC10 Q969S8 9/20 0.54
HDAC11 Q96DB2 9/20 0.54
HDAC6 Q9UBN7 9/20 0.54
HDAC9 Q9UKV0 9/20 0.54
HDAC5 Q9UQL6 9/20 0.54
NCOR2 Q9Y618 1/20 0.54
TMIGD3 P0DMS9 1/20 0.50
ADORA2A P29274 1/20 0.50
ADORA1 P30542 1/20 0.50
YTHDC1 Q96MU7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12963542 0.91 HDAC1 (0.69) HDAC1HDAC2CTSLHDAC8HDAC3
SCHEMBL8348688 0.86 HDAC1 (0.64) HDAC1HDAC2CTSLHDAC8HDAC3
SCHEMBL17628580 0.83 TMIGD3 (0.70) HDAC1HDAC2CTSLHDAC8HDAC3
SCHEMBL12933332 0.82 HDAC1 (0.59) HDAC1HDAC2CTSLHDAC8HDAC3
SCHEMBL6821043 0.81 CDK2 (0.62) HDAC1HDAC2CTSLADORA2AADORA1
SCHEMBL6817833 0.81 CDK1 (0.63) HDAC1HDAC2HDAC8
SCHEMBL13906495 0.81 TLR9 (0.59) HDAC1HDAC2CTSL
SCHEMBL6152650 0.80 CTSL (0.69) HDAC1CTSLTMIGD3ADORA2AADORA1
SCHEMBL6817859 0.80 CDK1 (0.74) HDAC1CTSLTMIGD3ADORA2AADORA1
SCHEMBL28726379 0.79 YTHDC1 (0.74) HDAC1HDAC2HDAC8HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1056745-B1 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMA INC (US) 2004-06-16 EP disclosed
US-6413974-B1 INHIBITORS OF CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; PREVENTING APOPTOSIS IN NEURONAL CELLS; ANTINEOPLASTIC AGENTS; NEURONAL INJURY AND DEGENERATION; CEREBROVASCULAR DISEASE AVENTIS PHARMACEUTICALS INC. 2002-07-02 US disclosed
EP-1056745-A2 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES Aventis Pharmaceuticals Inc. (US) 2000-12-06 EP disclosed
WO-1999043676-A2 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMACEUTICALS INC. (US) 1999-09-02 WO disclosed